BioNTech SE · NASDAQ:BNTX
BioNTech — FY2025 Earnings Presentation
33 slides from BioNTech's earnings presentation, Mar 10, 2026
Slide 1: Q4 & Full Year 2025 Financial Results & Corporate Update
4 Quarter & Full Year 2025 th Financial Results & Corporate Update March 10th, 2026
Slide 2: This Slide Presentation Includes Forward-Looking Statements
To be updated by Legal This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: expected changes to B
Slide 3: Progress Highlights, Oncology Execution, Financial Performance
1 Progress Highlights Prof. Ugur Sahin, Co-founder & Chief Executive Officer 2 Oncology Execution Prof. Özlem Türeci, Co-founder & Chief Medical Officer 3 Financial Performance Ramón Zapata, Chief Financial Officer 3
Slide 4: Progress Highlights
1 Progress Highlights Ugur Sahin, Co-founder & Chief Executive Officer 4
Slide 5: Translating Science into Survival
Translating Science into Survival Building a Global Immunotherapy Powerhouse 5
Slide 6: 2025 and Recent Achievements: Strong Performance and Pipeline Momentum
2025 and Recent Achievements: Strong Performance and Pipeline Momentum COVID-19 Market Advanced Key Executed Key Strengthened Leadership Oncology Programs Strategic Deals Financial Position Launched Over 25 phase 2 & 3 Strategic BMS Beat increased 2025 variant-adapted oncology trials ongoing2 partne
Slide 7: Oncology Late-Stage Acceleration
Oncology 1 Late-Stage Acceleration Key late-stage data readouts expected for first wave of oncology assets Focus in 2026 2 Combination Therapy Momentum Novel-novel pumitamig1 combination data readouts expected 3 Modalities to Disease Areas Transition to a focused disease area specific approach 1. Pa
Slide 8: Building a Multi-Product Company by 2030
Building a Multi-Product Company by 2030 Targeting 18+ Late-Stage/Pivotal Trial Readouts Through 2030+ Informing Multiple Launch Opportunities Expected Data Readouts2 Tumor Type Incidence1 Assets Late-Stage/Pivotal Trials 2026 2027 2028 2029 2030+ 1L NSCLC 400K Pumitamig3 ROSETTA Lung-02 Stage III u
Slide 9: Strategic Focus to Maximize Value for Patients and Shareholders
Strategic Focus to Maximize Value for Patients and Shareholders BioNTech New Company Becoming a multi-product company by 2030 Pioneering next-generation Focus Sharpening focus on growing late-stage clinical mRNA innovations with disruptive potential pipeline spanning immunomodulator, ADC and mRNA ca
Slide 10: Oncology Execution
2 Oncology Execution Özlem Türeci, Co-founder & Chief Medical Officer 10
Slide 11: Multi-Modal Immunotherapy Oncology Strategy
Multi-Modal Immunotherapy Oncology Strategy Focus on the critical IO pathways Immunomodulators • Targeting different complementary pathways in cancer immunity cycle may promote a durable anti-tumor effect Precise and potent modalities Synergy1 Synergy1 for fast onset tumor reduction Space • ADC as p
Slide 12: Pumitamig Strategy to Build a Proprietary IO Franchise
Pumitamig Strategy to Build a Proprietary IO Franchise Establish Expand Elevate SCLC Registrational-Intent Combining with our ADCs targeting 1L Ph3 (Global) 1L Gastric Ph2/3 (Global) • HER2 • HER3 2L Ph3 (China) 1L CRC Ph2/3 (Global) • TROP2 • EGFR x HER3 1L HNSCC Ph2/3 (Global) • B7H3 • Novel targe
Slide 13: Pumitamig Strategy to Build a Proprietary IO Franchise
Pumitamig Strategy to Build a Proprietary IO Franchise Establish Expand Elevate SCLC Registrational-Intent Combining with our ADCs targeting 1L Ph3 (Global) 1L Gastric Ph2/3 (Global) • HER2 • HER3 2L Ph3 (China) 1L CRC Ph2/3 (Global) • TROP2 • EGFR x HER3 1L HNSCC Ph2/3 (Global) • B7H3 • Novel targe
Slide 14: Establishing & Expanding Pumitamig in Combination with Current SoC
Establishing & Expanding Pumitamig1 in Combination with Current SoC Phase 2 Phase 3 Status Dose Selection Global Initiation Primary Completion SCLC 1L 2028 TNBC 1L 2029 1L 2029 NSCLC Stg. III unresectable 2026 2030+ 1L PD-L1 ≥50% 2026 2030+ CRC 1L Ongoing 2026 2026 2030 Gastric 1L Ongoing 2026 2026
Slide 15: Expanding BioNTech's Focus on Lung Cancer to Maximize Pipeline Potential
Expanding BioNTech’s Focus on Lung Cancer to Maximize Pipeline Potential Resectable Stage III Unresectable 1L metastatic 2L+ metastatic Incidence1 220K 65K 400K 230K Pumitamig2 Gotistobart3 Pumitamig2 + chemo ROSETTA LUNG-202 PRESERVE-003 (sq) IIT6 Pumitamig2 + chemo FixVac + Gotistobart3/ADCs Pumit
Slide 16: Executing a Parallel Three-Wave Strategy to Build a Proprietary IO Franchise
Executing a Parallel Three-Wave Strategy to Build a Proprietary IO Franchise Establish Expand Elevate SCLC Registrational-Intent Combining with our ADCs targeting 1L Ph3 (Global) 1L Gastric Ph2/3 (Global) • HER2 • HER3 2L Ph3 (China) 1L CRC Ph2/3 (Global) • TROP2 • EGFR x HER3 1L HNSCC Ph2/3 (Global
Slide 17: Single-Agent Activity of ADCs Being Explored Across Indications
Single-Agent Activity of ADCs Being Explored Across Indications Advancing Single-Agent Towards Commercial Stage Genitou- Additional T-Pam1 BC Phase 3 fully enrolled with Lung Breast rinary Gastrointestinal Gynecologic Tumors interim data expected in late 2026 NSCLC EGFRm HR+/ HER2- BC NSCLC AGA- T-P
Slide 18: Novel Combinations to Expand Pumitamig Opportunity Across Cancer Types
Novel Combinations to Expand Pumitamig Opportunity Across Cancer Types Building Foundations for Registrational Combinations Genitou- Additional Gyneco 10 novel-novel combination Lung Breast rinary Gastrointestinal Tumors -logic trials ongoing with pumitamig1 HR+/ HER2-BC NSCLC AGA- Melanoma Generati
Slide 19: Development Focus of mRNA Cancer Immunotherapy iNeST and FixVac Portfolios
Development Focus of mRNA Cancer Immunotherapy iNeST and FixVac Portfolios Autogene cevumeran1 BNT113 BNT1162 Adjuvant 1L Multiple settings CRC PDAC HPV16+ PD-L1 CPS ≥1 HNSCC NSCLC Phase 2 Phase 2 Phase 2/3 Phase 1 & 2 + Atezolizumab + Monotherapy mFOLFIRINOX + Pembrolizumab Mono & combo with IO & A
Slide 20: Catalyst-Rich Year Ahead with Multiple Expected 2026 Milestones
Catalyst-Rich Year Ahead with Multiple Expected 2026 Milestones Program Trial Readout Phase Indication Single arm Phase 2 2L+ HER2-expressing endometrial cancer Trastuzumab-pamirtecan3 Phase 35 interim analysis Chemo naïve HR+ HER2-low breast cancer Late-Stage Gotistobart2 Phase 35 interim analysis
Slide 21: Financial Performance
3 Financial Performance Ramón Zapata, Chief Financial Officer 21
Slide 22: Full Year 2025 Financial Results Compared to Guidance
Full Year 2025 Financial Results Compared to Guidance In € millions FY 2025 IFRS Results1 FY 2025 IFRS Guidance Total Revenues 2,870 2,600 – 2,800 R&D Expenses 2,105 2,000 – 2,200 SG&A Expenses 624 550 – 650 Capital Expenditures 198 200 – 250 for Operating Activities 1. Numbers have been rounded. Mo
Slide 23: Full Year 2025 Financial Results
Full Year 2025 Financial Results FY 2025 FY 2024 In € millions IFRS Results Adjusted Results2 IFRS Results Adjusted Results2 except per share data1 Revenues 2,870 2,870 2,751 2,751 Cost of sales (642) (611) (541) (493) Research and development expenses (2,105) (2,020) (2,254) (2,173) Sales, marketin
Slide 24: Fourth Quarter 2025 Financial Results
Fourth Quarter 2025 Financial Results 4Q 2025 4Q 2024 In € millions IFRS Results Adjusted Results2 IFRS Results Adjusted Results2 except per share data1 Revenues 907 907 1,190 1,190 Cost of sales (333) (302) (244) (205) Research and development expenses (505) (505) (612) (530) Sales, marketing, gene
Slide 25: Full Year 2026 Financial Guidance
Full Year 2026 Financial Guidance1 In € millions FY 2026 non-IFRS Guidance Total Revenues 2,000 – 2,300 Adjusted R&D Expenses 2,200 – 2,500 Adjusted SG&A Expenses 700 – 800 • Competitive market dynamics in the United States • Begin managing transition of multi-year contracts in Europe, and specifica
Slide 26: BioNTech Oncology Vision: Translating Science into Survival
BioNTech Oncology Vision: Translating Science into Survival 2025 2026 – 2029 2030 Advanced Strategy, Drive Oncology Diversified Multi- Matured Pipeline and Execution at Product Company De-risked Development Scale and Speed Progressed key programs into Advance combination therapy Build a diversified,
Slide 27: Thank you
Thank you
Slide 28: Appendix
__. Appendix BIONT=Cr
Slide 29: Reconciliation of Adjusted to IFRS Results – FY 2025 & 2024
Reconciliation of Adjusted to IFRS Results – FY 2025 & 2024 Financial Results FY 2025 FY 2024 In € millions IFRS Non-IFRS Adjusted IFRS Non-IFRS Adjusted except per share data1 Results Adjustments Results2 Results Adjustments Results2 Revenues 2,870 - 2,870 2,751 - 2,751 Cost of sales (642) 31 (611)
Slide 30: Reconciliation of Adjusted to IFRS Results – 4Q 2025 & 2024
Reconciliation of Adjusted to IFRS Results – 4Q 2025 & 2024 Financial Results 4Q 2025 4Q 2024 In € millions IFRS Non-IFRS Adjusted IFRS Non-IFRS Adjusted except per share data1 Results Adjustments Results2 Results Adjustments Results2 Revenues 907 - 907 1,190 - 1,190 Cost of sales (333) 31 (302) (24
Slide 31: BioNTech's Oncology Pipeline
BioNTech’s Oncology Pipeline Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 PLANNED BNT116 BNT324/DB-13113 Pumitamig1 + Autogene Pumitamig1 Pumitamig1 or BNT113 BNT324/ Trastuzumab Adv. NSCLC Multiple solid tumors BNT314/GEN10596 cevumeran2 2L ES-SCLC8 BNT325/DB-1305 + 1L HPV16+ HNSCC DB-13113 pamirtec
Slide 32: BioNTech's Infectious Diseases Pipeline
BioNTech’s Infectious Diseases Pipeline Phase 1 Phase 1/2 Phase 2 Commercial BNT1631 BNT162 + BNT1612 BNT1665 BNT1622,3 HSV COVID-19 – Influenza combination Mpox COVID-19 BNT351 BNT1644 HIV Tuberculosis BNT165 Malaria BNT1665 Mpox Antibody mRNA Partnered with: 1. University of Pennsylvania; 2. Pfize
Slide 33: Abbreviation Directory
Abbreviation Directory 4-1BB CD137 G7 markets Canada, France, Germany, Italy, Japan, GB, USA (sq) NSCLC (squamous) Non-small cell lung cancer nL nth line GB Great Britain OC Ovarian cancer AACR American Association for Cancer Research GBM Glioblastoma PCD Projected Commercialization Date ADC Antibod